Axsome Therapeutics Inc. (AXSM) has secured exclusive global rights to AZD7325, a novel oral GABAA receptor a2,3 subtype-selective positive allosteric modulator, from AstraZeneca.
The company plans to pursue AZD7325 as a potential treatment for epilepsy, with Phase 2 preparation expected to begin in 2026.
The CEO noted that adding AZD7325 expands Axsome's CNS pipeline with a differentiated early-stage molecule and supports the company's entry into the epilepsy treatment space, where patient need remains high.
AZD7325 has shown anti-seizure activity in preclinical studies and has been evaluated in more than 700 patients in Phase 1 trials, demonstrating a favorable safety and tolerability profile.
Axsome obtained the rights through the acquisition of Baergic Bio, Inc., and an amended license agreement with AstraZeneca. The deal includes upfront payments plus up to $79 million in potential milestones and tiered single-digit royalties on future global sales for both Baergic Bio shareholders and AstraZeneca.
AXSM currently trades at $134.41 or 0.95% lower on the NasdaqGM.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.